Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
47.98
+1.03 (2.19%)
At close: Jan 21, 2025, 4:00 PM
50.37
+2.39 (4.98%)
After-hours: Jan 21, 2025, 4:15 PM EST
Mirum Pharmaceuticals Revenue
Mirum Pharmaceuticals had revenue of $90.38M in the quarter ending September 30, 2024, with 89.37% growth. This brings the company's revenue in the last twelve months to $307.03M, up 112.14% year-over-year. In the year 2023, Mirum Pharmaceuticals had annual revenue of $186.37M with 141.85% growth.
Revenue (ttm)
$307.03M
Revenue Growth
+112.14%
P/S Ratio
7.21
Revenue / Employee
$1,162,985
Employees
264
Market Cap
2.30B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
MIRM News
- 8 days ago - Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates - Business Wire
- 11 days ago - Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 13 days ago - Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3) - Seeking Alpha
- 15 days ago - Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 27 days ago - Mirum Pharma: Buy At Dips For Volixibat Potential - Seeking Alpha
- 2 months ago - Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting - Business Wire
- 2 months ago - Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire